title: Changing end points in breast-cancer drug approval--the Avastin story.
authors.affiliation: Mathematics and Statistics Department, Boston University, Boston, USA.
authors.forename: Ralph B
authors.initials: RB
authors.lastname: D'Agostino
mesh_terms: D026683:Advisory Committees; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality; D018572:Disease-Free Survival; D017277:Drug Approval / Q000379:methods*; D004345:Drug Industry / Q000331:legislation & jurisprudence; D005260:Female; D006801:Humans; D017063:Outcome Assessment, Health Care / Q000379:methods*; D016019:Survival Analysis; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab